Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
You are here: Home » Top Stories

Top Stories

Print
Recent articles that are of ongoing interest...

Recent Articles

  Zhejiang Beta Pharma Forms JV with Amgen
May 9, 2013
Zhejiang Beta Pharma and Amgen will form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in China. Vectibix is a treatment for colorectal cancer. In addition to being experienced with targeted therapies, Zhejiang Beta also has a well-established China oncology sales network. The JV will be 51% owned by Zhejiang Beta, with Amgen holding the remainder. More details....

Stock Symbol: (NSDQ: AMGN)

Share this with colleagues:  

  Zhejiang Huahai and Oncobiologics Sign Biosimilar Pact
May 8, 2013
Zhejiang Huahai Pharma has joined with Oncobiologics, a New Jersey biologics startup, to form a partnership that will develop, manufacture and promote biosimilars. Huahai will have exclusive rights to make and market four Oncobiologics-developed biosimilars in China. The two companies will also sign a co-development and commercialization agreement to bring the four products -- generic versions of Humira, Rituxan, Avastin and Herceptin -- to 30 developed countries. More details....

Stock Symbol: (SHA: 600521)

Share this with colleagues:  

  Sagent Pharma Pays $25 Million to Buy out China JV Partner
May 6, 2013
Sagent Pharmaceuticals, a Chicago-area maker of generic injectable drugs, will acquire its partner’s 50% interest in a China JV for $25 million. Chengdu Kanghong Pharmaceuticals owned the other half of the JV, which was established in 2006 to build an FDA/GMP compliant manufacturing facility. Sagent apparently expects to use the China facility to manufacture products that supply the China and US markets. More details....

Stock Symbol: (NSDQ: SGNT)

Share this with colleagues:  

  Ascletis In-Licenses China Rights to HIV Drug from Janssen
Apr 30, 2013
Ascletis, a China-US drug developer, has in-licensed China rights to a next-generation HIV protease inhibitor from Janssen R&D Ireland, a subsidiary of Johnson & Johnson. Janssen believes the drug, known as TMC310911, is likely to prove more effective against drug-resistant strains of HIV than currently available PIs. The molecule is the third drug candidate in-licensed by Ascletis, which is also developing its own siRNA anti-cancer drug candidate. More details....

Stock Symbol: (NYSE: JNJ)

Share this with colleagues:  

  WuXi AppTec – "Every Client is a Partner"
Apr 29, 2013
ChinaBio® recently had a chance to talk with Richard Soll, PhD, Senior Vice President of Integrated Services, Head of Corporate Alliances at WuXi AppTec, China’s largest contract research organization. The subject was WuXi’s business strategy with a special focus on partnering. Although WuXi has various program structures in place for its clients, Dr. Soll stressed that all of their relationships are based on partnerships: “Every deal is a form of partnership, no matter how large or small it is.” he said. More details....
Share this with colleagues:  

  Ascletis and Roche to Develop Hepatitis C Treatment for China
Apr 15, 2013
Ascletis, a two-year-old China pharma startup, will collaborate with Roche to develop a Roche drug candidate for treatment of hepatitis C virus in China. Danoprevir is a protease inhibitor that has shown efficacy in European Phase II tests against HCV genotypes 1b and 4. Aslectis’ first deal was also a liver drug: an RNAi based treatment for liver cancer developed by Alnylam Pharma. More details....

Stock Symbols: (VX: ROG) (NSDQ: ALNY)

Share this with colleagues:  

  Lilly Invests $100 Million in China Animal Healthcare Ltd.
Apr 10, 2013
Eli Lilly’s animal health division, Elanco, will make a $100 million investment into China Animal Healthcare Ltd. The capital, which will give Elanco a 20% stake in China Animal Health, will be used, in part, to de-list China Animal Health from the Singapore Stock Exchange. China Animal Health IPO’d in Singapore in 2007, and then instituted a secondary listing in Hong Kong in 2010. Elanco said the two companies have set up a framework for future collaborations. More details....

Stock Symbols:  (NYSE: LLY) (SG: CAL; HK: 940)

Share this with colleagues:  

  Sanofi Looking for China M&A to Increase Revenue
Apr 1, 2013
Sanofi SA is actively seeking China M&A opportunities in the consumer healthcare and veterinary products sectors, according to the company’s CEO, Christopher Viehbacher, who was quoted in a Wall Street Journal article. The French big pharma wants to produce double-digit revenue growth in China during each of the next five years. Its China revenues were $1.3 billion last year, a 15% increase over the previous year. More details....

Stock Symbol: (NYSE: SNY)

Share this with colleagues:  

  Sinopharm Sells $515 Million of New Shares
Mar 29, 2013
Sinopharm Group, the biggest drug distributor in China, will raise $515 million by selling new Hong Kong-listed shares. The company said it would use the money to expand its sales network, which probably means a new round of M&A in China’s distribution sector. Because Sinopharm’s growth plans are so extensive, the company will be back in the market for more capital later this year, according to one analyst. More details....

Stock Symbol: (HK: 1099)

Share this with colleagues:  

  Dream Driven: Exclusive Interview with Dr. Jun Wang, Executive Director of BGI
Mar 19, 2013

ChinaBio® Today recently had the chance to interview Dr. Jun Wang, a co-founder of China’s sequencing giant, BGI-Shenzhen. Dr. Wang was named Executive Director of the company at the young age of 32. The company works with many of the big pharma and has established several major international partnerships. The driving force behind these relationships, according to Dr. Wang, is always the science. “We are a dream-driven organization,” he says. The dream is the promise of genomic science to improve human life, and BGI seems willing to enter any partnership that will advance genomic science, even if it doesn’t necessarily represent a profit opportunity. More details....

Share this with colleagues:  

 
more articles >>
Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2013
  May 29-30, 2013
Beijing, China

>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners